Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 11 of 11 entries
View as:

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05330858 Org: User:
Start: 03/17/22 End: 09/20/22 Due: 09/20/23

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT06962774 Org: User:
Start: 05/09/25 End: 12/31/25 Due: 12/31/26

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Phase: N/A Priority: Normal
NCT ID: NCT06588738 Org: User:
Start: 08/20/24 End: 12/31/25 Due: 12/31/26

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06586112 Org: User:
Start: 07/25/24 End: 12/31/25 Due: 12/31/26

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05600036 Org: User:
Start: 09/27/22 End: 07/25/23 Due: 07/25/24

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Phase: N/A Priority: Normal
NCT ID: NCT06952634 Org: User:
Start: 04/29/25 End: 12/31/25 Due: 12/31/26

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06846541 Org: User:
Start: 01/08/25 End: 11/30/28 Due: 11/30/29

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05966480 Org: User:
Start: 06/26/23 End: 09/01/27 Due: 09/01/28

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05431634 Org: User:
Start: 05/12/22 End: 12/31/22 Due: 12/31/23

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Phase: N/A Priority: Normal
NCT ID: NCT05953688 Org: User:
Start: 06/14/23 End: 08/13/24 Due: 08/13/25

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05739435 Org: User:
Start: 01/17/23 End: 12/30/26 Due: 12/30/27